- VernacularTitle:额颞叶痴呆的临床研究进展及展望
- Author:
Hua LU
1
;
Min CHU
1
;
Liyong WU
1
Author Information
- Publication Type:Journal Article
- Keywords: frontotemporal dementia; frontotemporal lobar degeneration; genetics; biomarkers; seed amplification assays; neuroimaging
- From: JOURNAL OF RARE DISEASES 2026;5(2):143-151
- CountryChina
- Language:Chinese
-
Abstract:
Frontotemporal dementia (FTD) refers to a spectrum of neurodegenerative disorders primarily affecting the frontal and/or temporal lobes. Given the marked clinical, genetic, and pathological heterogeneity, achieving accurate antemortem diagnosis and pathological subtyping remains a significant challenge. Recent genetic studies have revealed differences in the genetic landscape of FTD across populations; meanwhile, progress in body fluid and peripheral tissue biomarkers, seed amplification assays, and neuroimaging technologies has provided powerful tools for pathology-based early diagnosis. The research focus in the field of FTD treatment has gradually shifted from symptomatic treatment to disease-modifying therapies and neuromodulation. This review focuses on the latest advances in clinical research of FTD, aiming to provide a reference for the formulation of precise diagnosis and treatment strategies for this disease.

